KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Amneal Pharmaceuticals (AMRX) Restructuring Costs (2017 - 2025)

Historic Restructuring Costs for Amneal Pharmaceuticals (AMRX) over the last 9 years, with Q3 2025 value amounting to $143000.0.

  • Amneal Pharmaceuticals' Restructuring Costs fell 1686.05% to $143000.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $2.2 million, marking a year-over-year increase of 1290.49%. This contributed to the annual value of $2.4 million for FY2024, which is 3464.84% up from last year.
  • Per Amneal Pharmaceuticals' latest filing, its Restructuring Costs stood at $143000.0 for Q3 2025, which was down 1686.05% from $1.0 million recorded in Q2 2025.
  • In the past 5 years, Amneal Pharmaceuticals' Restructuring Costs ranged from a high of $7.3 million in Q4 2021 and a low of $82000.0 during Q2 2023
  • Moreover, its 5-year median value for Restructuring Costs was $493000.0 (2024), whereas its average is $903705.9.
  • As far as peak fluctuations go, Amneal Pharmaceuticals' Restructuring Costs plummeted by 9850.93% in 2022, and later skyrocketed by 36545.45% in 2025.
  • Amneal Pharmaceuticals' Restructuring Costs (Quarter) stood at $7.3 million in 2021, then plummeted by 98.51% to $109000.0 in 2022, then rose by 4.59% to $114000.0 in 2023, then soared by 332.46% to $493000.0 in 2024, then crashed by 70.99% to $143000.0 in 2025.
  • Its Restructuring Costs stands at $143000.0 for Q3 2025, versus $1.0 million for Q2 2025 and $571000.0 for Q1 2025.